Sign In
Buy PFE
$25.69
+0.335 (+1.32%)
At Close: Jun 04, 2026
Pfizer makes a $4.9 billion bet on obesity drugs with Metsera buyout deal
08:14am, Monday, 22'nd Sep 2025
Metsera's shareholders could see significant bonuses if certain milestones are reached.
Nasdaq 100 and S&P500: Intel Weakens, Metsera Spikes 59% on Pfizer Deal, Fed in Spotlight
08:05am, Monday, 22'nd Sep 2025
Dow, S&P500 futures pull back today as Metsera pops 59%, Intel drops, and markets question whether Fed policy will match rate cut forecasts.
This Anti-Obesity Stock Jumps 60% on $7.3 Billion Bid by Pfizer
07:42am, Monday, 22'nd Sep 2025
Pfizer said it would buy a clinical stage biopharma company for up to $7 billion, as it eyes the lucrative weight-loss drug market currently dominated by Eli Lilly and Novo Nordisk.
Pfizer to Buy Weight-Loss Drug Developer Metsera for Up to $7.3 Billion
07:02am, Monday, 22'nd Sep 2025
Pfizer has agreed to pay up to $7.3 billion for weight-loss drug developer Metsera in a deal that gets the New York drugmaker back into the burgeoning market for obesity drugs.
Pfizer to buy weight-loss drug developer Metsera for up to $4.9 billion
06:54am, Monday, 22'nd Sep 2025
Pfizer said on Monday it would acquire weight-loss drug developer Metsera for up to $4.9 billion to secure its position in the lucrative obesity treatment market.
Pfizer to Acquire Metsera and its Next-Generation Obesity Portfolio
06:45am, Monday, 22'nd Sep 2025
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Metsera, Inc. (NASDAQ: MTSR) today announced the companies have entered into a definitive agreement under which Pfizer will acquire Metsera, a cl
Pfizer close to acquiring Metsera for $7.3B, targeting breakthrough obesity drug
01:55am, Monday, 22'nd Sep 2025
Pfizer is making a bold move in the pharmaceutical world by closing in on a $7.3 billion deal to acquire Metsera, a biotech firm focused on next-generation anti-obesity drugs, news platform Financial
Pfizer closes in on $7.3 billion takeover of anti-obesity drugmaker Metsera, FT reports
12:04am, Monday, 22'nd Sep 2025
Pfizer is closing in on a potential $7.3 billion takeover of anti-obesity drug developer Metsera , the Financial Times reported on Sunday, citing unidentified sources.
3 Bargain Stocks for Investors on a Budget
05:05am, Sunday, 21'st Sep 2025
Money is tight for most Americans these days. Although the math suggests wages have mostly kept up with inflation, the reality is that paying the rent or the mortgage, buying groceries, or just keepin
Warren Buffett's ‘Secret Portfolio' Has 5 Perfect Dividend Stocks for Berkshire Hathaway
03:45pm, Saturday, 20'th Sep 2025
Warren Buffett remains one of the world's most prominent investors, renowned for his long-term buy-and-hold strategies and extensive portfolio of public and private holdings.
Healthcare Stocks Are at an Historic Low and a Turnaround Is on the Horizon
09:45am, Saturday, 20'th Sep 2025
According to some research, healthcare stocks are about as cheap as they have been in three decades. Many have experienced significant headwinds recently, but for opportunistic investors, now may be a
Prediction: These Could Be the Best-Performing Value Stocks Through 2030
04:44am, Saturday, 20'th Sep 2025
Some stocks are cheap for a reason. Others are cheap for a season.
Mizuho's Jared Holz: There's not much value left in vaccine stocks
11:40am, Friday, 19'th Sep 2025
Jared Holz, Mizuho healthcare senior strategist, joins CNBC's 'Squawk on the Street' to discuss outlooks on pharmaceuticals, what new government vaccine panel recommendations mean for the stocks, and
PFE vs. AZN: Which Cancer-Focused Drug Giant Is the Better Pick?
09:30am, Friday, 19'th Sep 2025
AstraZeneca and Pfizer both boast strong oncology pipelines, but growth paths, dividends and challenges set them apart for investors.
3 Unstoppable Dividend Stocks to Buy If There's a Stock Market Sell-Off
04:44am, Friday, 19'th Sep 2025
Think about a movie you've watched where everything seemed to be going great for the main character. What happened next?
